The group is currently focusing on identifying new ovarian and breast cancer susceptibility genes through massive sequencing (sets of exomes and genes) and genome-wide association studies. The functional characterisation and expression of variants of unknown clinical importance in genes that predispose to cancer. As well as identifying BRCA mRNA isoforms as a possible new mechanism of resistance against PARP inhibitors, and the study of microRNAs and long non-coding RNAs in the susceptibility to clinical toxicity induced by radiotherapy.

It is taking part in the European REQUITE project with prospective cohorts of cancer patients treated with radiotherapy for the biomarker trials on the side effects of radiotherapy.


Subscribe to our newsletters and be a part of Campus Life

Select the newsletter you want to receive:

By accepting these conditions, you are agreeing to the processing of your personal data for the provision of the services requested through this portal, and, if necessary, for any procedures required by the administrations or public bodies involved in this processing, and their subsequent inclusion in the aforementioned automated file. You may exercise your rights to access, rectification, cancellation or opposition by writing to, clearly stating the subject as "Exercising of Data Protection Rights".
Operated by: Hospital Universitari Vall d'Hebron - Institut Català de la Salut.
Purpose: Manage the user’s contact information.
Legitimisation: Express acceptance of the privacy policy.
Rights: To access, rectify, and delete personal information data, as well to the portability thereof and to limit and/or oppose their use.
Source: The interested party themselves.